Unfortunately, due to the low frequency of KRASG12C mutations in PDAC, there is not enough patient data to understand how pancreatic tumors will adapt to direct targeted KRAS inhibitor therapies. The gene discussed is KRAS; the disease is pancreatic neoplasm.